Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bie Verbist

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
BMC Bioinformatics|November 12, 2015
QQ-SNV: single nucleotide variant detection at low frequency by comparing the quality quantilesKoen Van der Borght, Kim Thys, Yves Wetzels, et al.
Drug Discovery Today|January 14, 2015
Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR projectBie Verbist, Günter Klambauer, Liesbet Vervoort, et al.
BMC Bioinformatics|April 19, 2015
ViVaMBC: estimating viral sequence variation in complex populations from illumina deep-sequencing data using model-based clusteringBie Verbist, Lieven Clement, Joke Reumers, et al.
BMC Genomics|October 6, 2025
Differential detection workflows for multi-sample single-cell RNA-seq dataJeroen Gilis, Laura Perin, Milan Malfait, et al.
Blood|May 26, 2016
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaJakub Krejcik, Tineke Casneuf, Inger S Nijhof, et al.
Plos Genetics|October 7, 2025
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myelomaIsabelle Bergiers, Murat Cem Köse, Sheri Skerget, et al.
Iscience|March 10, 2025
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-GNataša Obermajer, Adam Zwolak, Kelly van de Ven, et al.
Molecular Cancer Therapeutics|September 29, 2021
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor ActivityDirk Brehmer, Lijs Beke, Tongfei Wu, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
BMC Bioinformatics|November 12, 2015
QQ-SNV: single nucleotide variant detection at low frequency by comparing the quality quantilesKoen Van der Borght, Kim Thys, Yves Wetzels, et al.
Drug Discovery Today|January 14, 2015
Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR projectBie Verbist, Günter Klambauer, Liesbet Vervoort, et al.
BMC Bioinformatics|April 19, 2015
ViVaMBC: estimating viral sequence variation in complex populations from illumina deep-sequencing data using model-based clusteringBie Verbist, Lieven Clement, Joke Reumers, et al.
BMC Genomics|October 6, 2025
Differential detection workflows for multi-sample single-cell RNA-seq dataJeroen Gilis, Laura Perin, Milan Malfait, et al.
Blood|May 26, 2016
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaJakub Krejcik, Tineke Casneuf, Inger S Nijhof, et al.
Plos Genetics|October 7, 2025
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myelomaIsabelle Bergiers, Murat Cem Köse, Sheri Skerget, et al.
Iscience|March 10, 2025
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-GNataša Obermajer, Adam Zwolak, Kelly van de Ven, et al.
Molecular Cancer Therapeutics|September 29, 2021
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor ActivityDirk Brehmer, Lijs Beke, Tongfei Wu, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 2